Sajjad Abedian

Sajjad Abedian

Auto-generated profile, based on publicly available information

Sajjad Abedian

Information Technologies and Services Department, Weill Cornell Medicine, New York, New York

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YZYongkang Zhang
Yongkang Zhang
YZYiye Zhang
Yiye Zhang
ESEvan Sholle
Evan Sholle
SASajjad Abedian
Sajjad Abedian
MSMarianne Sharko
Marianne Sharko
JAJessica S. Ancker
Jessica S. Ancker
Early hospital readmissions or deaths are key healthcare quality measures in pay-for-performance programs. Predictive models could identify patients at higher risk of readmission or death and target interventions. However, existing models usually do not incorporate social determinants of health (SDH) information, although this information is of great importance to address health disparities related to social risk factors. The objective of this study is to examine the impact of social determinants of health on predictive models for potentially avoidable 30-day readmission. We extracted electronic health record data for 19,941 hospital admissions between January 2015 and November 2017 at an academic medical center in New York City. We applied the Simplified HOSPITAL score model to predict potentially avoidable 30-day readmission or death and examined if incorporating individual- and community-level SDH could improve the prediction using cross-validation. We calculated the C-statistic for discrimination, Brier score for accuracy, and Hosmer–Lemeshow test for calibration for each model using logistic regression. Analysis was conducted for all patients and three subgroups that may be disproportionately affected by social risk factors, namely Medicaid patients, patients who are 65 or older, and obese patients. The Simplified HOSPITAL score model achieved similar performance in our sample compared to previous studies. Adding SDH did not improve the prediction among all patients. However, adding individual- and community-level SDH at the US census tract level significantly improved the prediction for all three subgroups. Specifically, C-statistics improved from 0.70 to 0.73 for Medicaid patients, from 0.66 to 0.68 for patients 65 or older, and from 0.70 to 0.73 for obese patients. Patients from certain subgroups may be more likely to be affected by social risk factors. Incorporating SDH into predictive models may be helpful to identify these patients and reduce health disparities associated with vulnerable social conditions.

25 October 2021 in JCO Clinical Cancer Informatics
Verified
Journal Article
Closed access
SASajjad Abedian
Sajjad Abedian
ESEvan T. Sholle
Evan T. Sholle
PAPrakash M. Adekkanattu
Prakash M. Adekkanattu
MCMarika M. Cusick
Marika M. Cusick
SWStephanie E. Weiner
Stephanie E. Weiner
TCThomas R. Campion
Thomas R. Campion
PURPOSE: Typically stored as unstructured notes, surgical pathology reports contain data elements valuable to cancer research that require labor-intensive manual extraction. Although studies have described natural language processing (NLP) of surgical pathology reports to automate information extraction, efforts have focused on specific cancer subtypes rather than across multiple oncologic domains. To address this gap, we developed and evaluated an NLP method to extract tumor staging and diagnosis information across multiple cancer subtypes. METHODS: The NLP pipeline was implemented on an open-source framework called Leo. We used a total of 555,681 surgical pathology reports of 329,076 patients to develop the pipeline and evaluated our approach on subsets of reports from patients with breast, prostate, colorectal, and randomly selected cancer subtypes. RESULTS: Averaged across all four cancer subtypes, the NLP pipeline achieved an accuracy of 1.00 for International Classification of Diseases, Tenth Revision codes, 0.89 for T staging, 0.90 for N staging, and 0.97 for M staging. It achieved an F1 score of 1.00 for International Classification of Diseases, Tenth Revision codes, 0.88 for T staging, 0.90 for N staging, and 0.24 for M staging. CONCLUSION: The NLP pipeline was developed to extract tumor staging and diagnosis information across multiple cancer subtypes to support the research enterprise in our institution. Although it was not possible to demonstrate generalizability of our NLP pipeline to other institutions, other institutions may find value in adopting a similar NLP approach—and reusing code available at GitHub—to support the oncology research enterprise with elements extracted from surgical pathology reports.

14 May 2021 in Annals of Pharmacotherapy
Verified
Journal Article
Open access
PDF file
CWCorey J. Witenko
Corey J. Witenko
ALAudrey J. Littlefield
Audrey J. Littlefield
SASajjad Abedian
Sajjad Abedian
AAAnjile An
Anjile An
PBPhilip S. Barie
Philip S. Barie
KBKaren Berger
Karen Berger
Background: Propofol is commonly used to achieve ventilator synchrony in critically ill patients with coronavirus disease 2019 (COVID-19), yet its safety in this patient population is unknown. Objective: To evaluate the safety, in particular the incidence of hypertriglyceridemia, of continuous infusion propofol in patients with COVID-19. Methods: This was a retrospective study at 1 academic medical center and 1 affiliated teaching hospital in New York City. Adult, critically ill patients with COVID-19 who received continuous infusion propofol were included. Patients who received propofol for <12 hours, were transferred from an outside hospital while on mechanical ventilation, or did not have a triglyceride concentration obtained during the infusion were excluded. Results: A total of 252 patients were included. Hypertriglyceridemia (serum triglyceride concentration ≥ 400 mg/dL) occurred in 38.9% of patients after a median cumulative dose of 4307 mg (interquartile range [IQR], 2448-9431 mg). The median time to triglyceride elevation was 3.8 days (IQR, 1.9-9.1 days). In the multivariable regression analysis, obese patients had a significantly greater odds of hypertriglyceridemia (odds ratio = 1.87; 95% CI = 1.10, 3.21). There was no occurrence of acute pancreatitis. The incidence of possible propofol-related infusion syndrome was 3.2%. Conclusion and Relevance: Hypertriglyceridemia occurred frequently in patients with COVID-19 who received propofol but did not lead to acute pancreatitis. Elevated triglyceride concentrations occurred more often and at lower cumulative doses than previously reported in patients without COVID-19. Application of these data may aid in optimal monitoring for serious adverse effects of propofol in patients with COVID-19.

4 June 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SWShannon Wuller
Shannon Wuller
NSNora G. Singer
Nora G. Singer
CLColby Lewis
Colby Lewis
EKElizabeth W. Karlson
Elizabeth W. Karlson
GSGrant S. Schulert
Grant S. Schulert
RIRecover Pcornet Ehr Cohort On Behalf Of The Recover Initiative
Recover Pcornet Ehr Cohort On Behalf Of The Recover Initiative
SARS-CoV-2 infection has been associated with increased autoimmune disease risk. Past studies have not aligned regarding the most prevalent autoimmune diseases after infection, however. Furthermore, the relationship between infection severity and new autoimmune disease risk has not been well examined. We used RECOVER’s electronic health record (EHR) networks, N3C, PCORnet, and PEDSnet, to estimate types and frequency of autoimmune diseases arising after SARS-CoV-2 infection and assessed how infection severity related to autoimmune disease risk. We identified patients of any age with SARS-CoV-2 infection between April 1, 2020 and April 1, 2021, and assigned them to a World Health Organization COVID-19 severity category for adults or the PEDSnet acute COVID-19 illness severity classification system for children (30 days after SARS-CoV-2 infection index date and occurring ≥1 day apart. We calculated overall and infection severity-stratified incidence ratesper 1000 person-years for all autoimmune diseases. With least severe COVID-19 severity as reference, survival analyses examined incident autoimmune disease risk. The most common new-onset autoimmune diseases in all networks were thyroid disease, psoriasis/psoriatic arthritis, and inflammatory bowel disease. Among adults, inflammatory arthritis was the most common, and Sjögren’s disease also had high incidence. Incident type 1 diabetes and hematological autoimmune diseases were specifically found in children. Across networks, after adjustment, patients with highest COVID-19 severity had highest risk for new autoimmune disease vs. those with least severe disease (N3C: adjusted Hazard Ratio, (aHR) 1.47 (95%CI 1.33–1.66); PCORnet aHR 1.14 (95%CI 1.02–1.26); PEDSnet: aHR 3.14 (95%CI 2.42–4.07)]. Overall, severe acute COVID-19 was most strongly associated with autoimmune disease risk in three EHR networks.

5 September 2021 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
PDF file
CWCorey J. Witenko
Corey J. Witenko
ALAudrey J. Littlefield
Audrey J. Littlefield
SASajjad Abedian
Sajjad Abedian
AAAnjile An
Anjile An
PBPhilip S. Barie
Philip S. Barie
KBKaren Berger
Karen Berger

31 October 2025 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
LCLuchang Cui
Luchang Cui
JLJuhong Lee
Juhong Lee
JMJuliet Miller
Juliet Miller
MTMinmeng Tang
Minmeng Tang
SASajjad Abedian
Sajjad Abedian
YSYiwey Shieh
Yiwey Shieh
Background: The proportion of lung cancers affecting individuals who have never smoked is growing, with these cancers being prone to harbor mutations in the EGFR gene. Little is known about risk factors and prognostic indicators for EGFR-mutant cancers, with current research limited by the scarcity of datasets integrating genomic, clinical, and environmental data. Methods: We created the Meyer Cancer Center Molecularly Enhanced Lung Cancer Database (MCC-MELD), including lung cancer cases from a large catchment area in New York City. We identified cases through linkage to our institution’s cancer registry and a clinician-initiated, manually curated database. We linked all cases to the electronic health record and in-house tumor genomic testing results. We used natural language processing (NLP) to extract unstructured genomic testing results and detailed smoking history. We linked geocoded addresses to detailed area-level measures. Results: MCC-MELD contains 9,573 patients with lung cancer diagnosed from 1988 to 2024, of whom 20% were non-Hispanic Asian, 14% were non-Hispanic Black, and 8% were Hispanic. We identified 1,092 (11.4%) EGFR-mutant cancers, with NLP identifying 397 cases not identified by structured data. NLP showed high accuracy in ascertaining EGFR status (97%) and quantitative smoking history variables (90%–98%). Never smokers made up 16% of the cases in MCC-MELD. Conclusions: MCC-MELD is an NLP-enhanced database containing clinical information, genomic testing results, and linkages to area-level data for patients with lung cancer from a diverse urban setting. Impact: This resource can facilitate studies on lung cancer risk factors, treatment patterns, and outcomes by EGFR and other driver mutation status.